杏林製薬の株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2024/03/04 | 1,788 | 1,793 | 1,772 | 1,776 | -12 | -0.7% | 51,100 |
| 2024/03/01 | 1,793 | 1,795 | 1,774 | 1,788 | +7 | +0.4% | 59,200 |
| 2024/02/29 | 1,781 | 1,784 | 1,771 | 1,781 | -6 | -0.3% | 87,600 |
| 2024/02/28 | 1,795 | 1,809 | 1,782 | 1,787 | -8 | -0.4% | 62,900 |
| 2024/02/27 | 1,794 | 1,811 | 1,790 | 1,795 | +3 | +0.2% | 85,400 |
| 2024/02/26 | 1,790 | 1,803 | 1,786 | 1,792 | +10 | +0.6% | 84,700 |
| 2024/02/22 | 1,776 | 1,785 | 1,771 | 1,782 | +17 | +1% | 87,900 |
| 2024/02/21 | 1,780 | 1,787 | 1,759 | 1,765 | -19 | -1.1% | 69,700 |
| 2024/02/20 | 1,781 | 1,798 | 1,780 | 1,784 | +12 | +0.7% | 83,600 |
| 2024/02/19 | 1,748 | 1,775 | 1,741 | 1,772 | +36 | +2.1% | 71,500 |
| 2024/02/16 | 1,730 | 1,748 | 1,724 | 1,736 | +24 | +1.4% | 77,900 |
| 2024/02/15 | 1,750 | 1,751 | 1,712 | 1,712 | -28 | -1.6% | 82,000 |
| 2024/02/14 | 1,782 | 1,783 | 1,734 | 1,740 | -40 | -2.2% | 103,700 |
| 2024/02/13 | 1,760 | 1,784 | 1,757 | 1,780 | +20 | +1.1% | 88,900 |
| 2024/02/09 | 1,750 | 1,770 | 1,748 | 1,760 | +2 | +0.1% | 119,200 |
| 2024/02/08 | 1,764 | 1,772 | 1,754 | 1,758 | -6 | -0.3% | 85,600 |
| 2024/02/07 | 1,760 | 1,776 | 1,757 | 1,764 | -12 | -0.7% | 114,100 |
| 2024/02/06 | 1,792 | 1,798 | 1,770 | 1,776 | -4 | -0.2% | 66,600 |
| 2024/02/05 | 1,793 | 1,793 | 1,773 | 1,780 | +6 | +0.3% | 77,500 |
| 2024/02/02 | 1,780 | 1,785 | 1,767 | 1,774 | -3 | -0.2% | 55,500 |
| 2024/02/01 | 1,773 | 1,779 | 1,761 | 1,777 | -7 | -0.4% | 65,700 |
| 2024/01/31 | 1,771 | 1,784 | 1,756 | 1,784 | +7 | +0.4% | 74,700 |
| 2024/01/30 | 1,794 | 1,800 | 1,777 | 1,777 | -14 | -0.8% | 43,400 |
| 2024/01/29 | 1,779 | 1,794 | 1,779 | 1,791 | +12 | +0.7% | 34,000 |
| 2024/01/26 | 1,795 | 1,795 | 1,778 | 1,779 | -20 | -1.1% | 63,100 |
| 2024/01/25 | 1,793 | 1,800 | 1,788 | 1,799 | +4 | +0.2% | 66,700 |
| 2024/01/24 | 1,798 | 1,801 | 1,783 | 1,795 | -16 | -0.9% | 49,800 |
| 2024/01/23 | 1,809 | 1,829 | 1,809 | 1,811 | +10 | +0.6% | 58,700 |
| 2024/01/22 | 1,795 | 1,811 | 1,795 | 1,801 | +6 | +0.3% | 29,800 |
| 2024/01/19 | 1,817 | 1,821 | 1,782 | 1,795 | -31 | -1.7% | 61,400 |
| 2024/01/18 | 1,826 | 1,829 | 1,816 | 1,826 | +7 | +0.4% | 39,800 |
| 2024/01/17 | 1,845 | 1,845 | 1,818 | 1,819 | -12 | -0.7% | 44,700 |
| 2024/01/16 | 1,840 | 1,848 | 1,823 | 1,831 | -9 | -0.5% | 49,500 |
| 2024/01/15 | 1,812 | 1,840 | 1,812 | 1,840 | +28 | +1.5% | 58,000 |
| 2024/01/12 | 1,835 | 1,838 | 1,803 | 1,812 | -15 | -0.8% | 58,800 |
| 2024/01/11 | 1,834 | 1,835 | 1,818 | 1,827 | +1 | +0.1% | 62,800 |
| 2024/01/10 | 1,814 | 1,828 | 1,804 | 1,826 | +20 | +1.1% | 75,700 |
| 2024/01/09 | 1,792 | 1,814 | 1,792 | 1,806 | +13 | +0.7% | 54,100 |
| 2024/01/05 | 1,812 | 1,812 | 1,787 | 1,793 | -19 | -1% | 56,400 |
| 2024/01/04 | 1,779 | 1,812 | 1,754 | 1,812 | +32 | +1.8% | 105,000 |
| 2023/12/29 | 1,777 | 1,785 | 1,769 | 1,780 | +7 | +0.4% | 47,000 |
| 2023/12/28 | 1,765 | 1,776 | 1,763 | 1,773 | ±0 | ±0% | 40,900 |
| 2023/12/27 | 1,757 | 1,774 | 1,753 | 1,773 | +16 | +0.9% | 60,800 |
| 2023/12/26 | 1,760 | 1,764 | 1,746 | 1,757 | +7 | +0.4% | 53,400 |
| 2023/12/25 | 1,796 | 1,796 | 1,750 | 1,750 | -18 | -1% | 59,900 |
| 2023/12/22 | 1,746 | 1,771 | 1,746 | 1,768 | +16 | +0.9% | 66,100 |
| 2023/12/21 | 1,760 | 1,760 | 1,748 | 1,752 | -8 | -0.5% | 68,700 |
| 2023/12/20 | 1,753 | 1,771 | 1,753 | 1,760 | +7 | +0.4% | 77,000 |
| 2023/12/19 | 1,749 | 1,756 | 1,738 | 1,753 | +20 | +1.2% | 83,200 |
| 2023/12/18 | 1,728 | 1,735 | 1,712 | 1,733 | -10 | -0.6% | 57,400 |
51～
100
件表示中 / 3457件
類似銘柄と比較する
現在ご覧いただいている「杏林製薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| 杏林製薬 | 171,200円 | +3.2% | +4.5% | 3.04% | 19.67倍 | 0.75倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
| 持田薬 | 305,500円 | +3.0% | +27.5% | 2.62% | 19.34倍 | 0.85倍 |
|
医薬中堅。高脂血症薬、降圧薬など循環器系得意。婦人科系にも強み。消化器系育成。化粧品も |
| 鳥居薬 | 389,500円 | +7.3% | +16.8% | 3.08% | 23.30倍 | 0.91倍 |
|
ＪＴ傘下。自社製品の腎・透析、アレルゲン等の開発強化。柱の抗ＨＩＶ薬の販売権喪失が直撃 |
| ジーエヌアイ | 217,800円 | +52.1% | +23.3% | 0.00% | 15.39倍 | 3.21倍 |
|
創薬ベンチャー。米国で人工骨も。中国の特発性肺線維症薬で高シェア、米中に研究開発機能 |
| ゼリア新薬 | 200,900円 | +9.6% | +17.5% | 2.29% | 11.35倍 | 1.11倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
市場注目の銘柄
チャート関連のコラム
